Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine

CA27.29 as a tumour marker for risk evaluation and therapy monitoring in primary breast cancer patients.

PMID 27481512


Several trials showed that tumour markers are associated with an impaired prognosis for breast cancer. Whether earlier treatment can improve the course of the disease remains controversial. The SUCCESS Trial compares FEC (500/100/500)-docetaxel (100) vs. FEC (500/100/500)-docetaxel/gemcitabine (75/2000) as well as 2 vs. 5xa0years of zoledronate in high-risk primary breast cancer patients. In 2669 patients, CA27.29 was measured before and after chemotherapy with the ST AIA-PACK CA27.29 reagent for the AIA-600II automated enzyme immunoassay (Tosoh Bioscience, Belgium). Values above 31xa0U/ml were considered positive. Of the patients, 7.6xa0% (nxa0=xa0202, mean 19, range 3-410) and 19.1xa0% (nxa0=xa0511, mean 21, range 3-331) had elevated marker levels before and after chemotherapy, respectively. Of the patients, 4.9 and 78xa0% showed elevated and low CA27.29, respectively, at both time points. After treatment, 35xa0% of the pre-therapy positive patients were negative, and 15xa0% of the initially negative patients became positive. The correlation between both time points was significant (pxa0